McClarren Financial Advisors’s Genmab GMAB Stock Holding History

McClarren Financial Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	–	–	390
2023 Q1	$0	Hold	3	–	–	﹤0.01%	385
2022 Q4	$0	Buy	+3	New	+$124	﹤0.01%	393

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

McClarren Financial Advisors's GMAB Position: Q2 2023 in Review

McClarren Financial Advisors sold out of Genmab (GMAB) in Q2 2023, closing a stake of 3 shares.

McClarren Financial Advisors first reported a position in GMAB in Q4 2022 and held it in 2 quarters. The position peaked at $0 in Q1 2023. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

McClarren Financial Advisors reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
McClarren Financial Advisors sold 3 Genmab shares in Q2 2023.
McClarren Financial Advisors first reported a position in Genmab in Q4 2022 and held it in 2 quarters.
McClarren Financial Advisors's Genmab position peaked at $0 in Q1 2023.
213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on McClarren Financial Advisors's 13F filing for Q2 2023, filed 7 Aug 2023.